Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tiffany Pluto

Family Medicine Scottdale, PA Doctor of Osteopathy

NPI 1073515441 CMS profile 93566

109 Crossroads Rd, Suite 201, Scottdale, PA 15683

Open in the dashboard

General payments

$980

4 records reported · program years 2019–2025

Research payments

$38,446

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,763,919 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Tiffany Pluto of Scottdale, PA is reported in the CMS Open Payments database as having received $980 across 4 general payments and $38,446 in research payments paid to them. Separately, studies naming them as principal investigator received $4,763,919 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125 1
2024 Research $38,128 1
2023 Research $318 1
2020 General $840 2
2019 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Pluto
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Tiffany Pluto were reported at $125. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Tiffany Pluto Family Medicine median Middle half National median
2019 $15 $150 $41–$543 $163
2020 $840 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $125 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $792 1 payment
  2. Intuitive Surgical, Inc. $125 1 payment
  3. AstraZeneca Pharmaceuticals LP $48 1 payment
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $792 1 payment
  2. Food and Beverage $173 2 payments
  3. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. ENTRESTO $792 1 payment
  2. Da Vinci Surgical System $125 1 payment
  3. FARXIGA $48 1 payment
  4. SPIRIVA RESPIMAT $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $38,446 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 181 drugs

Part D claims

12,518

Median for Family Practice: 1,826

Drug cost

$923,873

Median for Family Practice: $120,094

Branded share of claims

21.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 127 $142,085
Eliquis Apixaban Brand 120 $114,330
Mounjaro Tirzepatide Brand 81 $86,355
Jardiance Empagliflozin Brand 78 $67,373
Xarelto Rivaroxaban Brand 49 $53,164
Farxiga Dapagliflozin Propanediol Brand 66 $48,602
Trulicity Dulaglutide Brand 38 $43,958
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 52 $35,207
Rybelsus Semaglutide Brand 21 $22,257
Invokana Canagliflozin Brand 29 $19,081

The 10 drugs with the highest cost, of 181 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$57,584

Of which drugs: $3,688

Medicare patients

204

Average age 71

Services billed

947

126 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 25%
Ischemic heart disease 23%
COPD 20%
Cancer 18%
Chronic kidney disease 17%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 31 31 $2,536

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record